Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18928969.
- Also identified by DOI 10.1016/j.ajog.2008.06.051.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Peripartum cardiomyopathy (PPCM) is a rare disease of unclear etiology with a frequent poor outcome, despite optimal medical therapy. Recent experimental data implicate a causal role of prolactin. We report a patient with PPCM who responded well to treatment with Bromocriptine in addition to standard therapy of heart failure.
Medical subject headings
- Bromocriptine
- Cardiomyopathies
- HELLP Syndrome
- Heart Failure
- Hormone Antagonists
- Pregnancy Complications, Cardiovascular